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1. Introduction  
1.1 Epidemiology 
Approximately 20% of the European population report severe chronic pain (Breivik et al., 
2006), with higher prevalences in women and in lower income groups (Gerdle et al., 2004; 
Larsson et al., 2007). Common chronic pain conditions are localized neck-shoulder pain 
including trapezius myalgia (prevalence in population 10-20%) (Lidgren, 2008), chronic 
whiplash associated disorders (WAD) (prevalence in the population 1.5%) (Guez et al., 
2002), and chronic widespread pain (CWSP) (prevalence in population 5-10%) (Gerdle et al., 
2008a). Chronic pain is associated with disability, low quality of life, and substantial 
socioeconomic costs (Breivik et al., 2006; Phillips, 2006; SBU, 2006).  
1.2 Development of chronic myalgia – Chronic trapezius myalgia as an example 
There is a connection between physical demands, psychosocial demands, and the risk of 
persistent muscle pain (Bernard, 1997; Punnett & Wegman, 2004); however, the mechanisms 
behind chronic myalgia are poorly understood. Myalgia usually starts with a feeling of 
tiredness and stiffness. At the beginning, the initial intermittent stage, pain can be alleviated 
for short or long periods. Chronic regional myalgia (CRM) in the neck-shoulder area often 
gradually becomes more easily triggered and more diffuse and can be spread to include most 
of the body (CWSP). CWSP includes fibromyalgia, a subgroup characterized by widespread 
hyperalgesia. The risk factors for the transition from a local/regional pain condition to CWSP 
are poorly understood (Larsson et al., in press). The diagnoses CRM (e.g., chronic trapezius 
myalgia) and CWSP are settled by careful anamnesis and clinical examinations that reveal 
tender muscle at palpation corresponding to the reported painful areas.  
1.3 Neurobiological alterations in chronic pain 
Acute pain results from a complex integrated series of events at peripheral and central 
levels. In healthy subjects, mechanisms related to acute pain might not necessarily be valid 
in subjects with subchronic, intermittent, or chronic pain. 
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Pace et al. suggested two types of persistent chronic pain: 1) nociceptive/inflammatory pain 
and 2) neuropathic pain (Pace et al., 2006). The present study mainly discusses 
nociceptive/inflammatory pain. Chronic pain is more complex than acute pain as extensive 
short-term and long-term plastic and sometimes permanent changes (including peripheral 
and/or central hyperexcitability/sensitization) of the pain transmission system can occur at 
different levels (Kuner, 2010; Reichling & Levine, 2009) and by the modification of 
psychological (e.g., attentional, emotional, and anticipation status) and context factors 
(Grachev et al., 2000; Hunt & Mantyh, 2002; Petersen-Felix & Curatolo, 2002; Schmidt-Wilcke, 
2008; Wilder-Smith et al., 2002; Woolf & Salter, 2000).  Different structures in the brain – 
vaguely labelled as the pain matrix (Iannetti & Mouraux, 2010; Lee & Tracey, 2010; Legrain et 
al., 2011) – are dynamically involved in processing of nociception and pain  (including 
emotions, cognitions, and motivation) (Ossipov et al., 2010). In patients with chronic pain 
conditions, a pain matrix shows different types of alterations including morphological changes 
(Apkarian, 2008; Schweinhardt & Bushnell, 2010), indicating that different chronic pain 
conditions exhibit unique anatomical ”brain signatures” (Baliki et al., 2011).  
Descending supraspinal control of spinal nociception originates from many brain regions 
(Heinricher et al., 2009; Ossipov et al., 2010). The descending supraspinal control includes a 
dynamic balance between inhibiting and facilitating mechanisms that can be altered due to 
behavioural, emotional, and pathological states (Heinricher et al., 2009; Ossipov et al., 2010). 
When the system shifts towards inhibition, hyposensibility or lack of pain in spite of inputs 
from peripheral tissue may result (Heinricher et al., 2009; Kuner, 2010; Porreca et al., 2002; 
Ren & Dubner, 2002; Robinson & Zhuo, 2002; Wilder-Smith et al., 2002). The evolutionary 
value of this is that the organism can ignore pain during critical situations, e.g., flight or 
fight scenarios (Kuner, 2010). A facilitating shift of the descending system has been reported 
for different groups of patients with persistent pain (Heinricher et al., 2009; Julien et al., 
2005; Kuner, 2010; Porreca et al., 2002; Ren & Dubner, 2002; Robinson & Zhuo, 2002; Wilder-
Smith et al., 2002). 
Decreased production of substances such as endorphins or gamma-aminobutyric acid 
(GABA), the most common inhibitory neurotransmitter in the central nervous system, may 
contribute to disturbances in pain inhibition. Animal and human studies have confirmed 
that the endogenous opioid system and GABA play a role in the modulation of pain. 
However, the understanding of the mechanisms, including the peripheral balances between 
nociceptive and anitinociceptive processes, behind chronic myalgia is incomplete. The 
analgesic properties of exogenous cannabinoids have been recognized for many years. Data 
clearly implicate endocannabinoids as endogenous tonic pain controlling molecules 
(Agarwal et al., 2007; Richardson et al., 1998; Walker & Huang, 2002), but little is known as 
to whether peripheral endocannabinoid signalling is disturbed in human pain. 
1.4 Muscle nociception and peripheral sensitization 
Neurophysiological studies have indicated that small-diameter, slowly conducting afferent 
nerve fibres from skeletal muscle –free nerve endings of group III (Aδ) and IV afferent (C) 
fibres – have to be excited to elicit pain (Mense, 2003). The nociceptor is specialized to 
respond to noxious stimuli and communicate this information to the CNS. Nociceptors or 
noxious stimulus detectors (Woolf & Ma, 2007) are sensitive to chemical substances released 
from damaged or overloaded cells and excessive tissue deformation (Coutaux et al., 2005; 
Mense, 1993). Nociceptors respond to single or combinations of stimuli: noxious mechanical 
www.intechopen.com
Potential Muscle Biomarkers of Chronic Myalgia in Humans –  
A Systematic Review of Microdialysis Studies 
 
105 
stimuli, temperature, and chemical substances such as serotonin H+, (5-HT), bradykinin 
(BKN), glutamate, prostaglandin E2 (PGE2), substance P, nerve growth factor (NGF), ATP, 
and potassium (Coutaux et al., 2005; Mense, 1993; 2009). Administration of any of these 
substances, alone or in combination, results in excitation of nociceptors (Mense, 1993). The 
relative effectiveness of these substances is unknown. In a pathophysiological situation due 
to trauma or inflammation, a combination of substances acts on the nociceptors (the 
inflammatory “soup” or “cocktail”)(Mense, 2009). The nociceptor is not a static detector as 
plastic changes can occur such as peripheral sensitization (Woolf & Ma, 2007). A sensitized 
nociceptor has a lowered threshold for activation and can thus be activated by stimuli that 
are normally innocuous (Coutaux et al., 2005; Mense, 1993). Several substances – e.g., H+, 
NO, K+, ATP, bradykinin (BKN), PGE2, NGF, TNF-ǂ, IL-6, and glutamate – are known to 
cause peripheral sensitization (Coutaux et al., 2005; Mense, 2009; Momin & McNaughton, 
2009). The action of these substances is mediated by their specific receptors mainly found in 
three classes: 1) G protein coupled receptors; 2) receptor tyrosine kinases; and 3) ionotropic 
receptors/ion channels (Linley et al., 2010). Sensitization is often accompanied by an 
increase in the sensitive area (Mense, 1993). In addition, other alterations of the nociceptors, 
including activation of silent nociceptors, have been found as the result of injury or 
inflammation (Schaible et al., 2009). When persistent alterations in the nociceptors as the 
result of induced gene transcription and protein synthesis drive pain in the absence of 
noxious stimuli these alterations represent a pathological condition (Woolf & Ma, 2007).  
1.5 The bio-psycho-social model of chronic pain 
The net result of the above mentioned and other alterations are clinically registered as pain 
hypersensitivity – an increased responsiveness to nociception and sometimes to innocuous 
stimuli. In clinical management of chronic pain, a bio-psycho-social model (Gatchel et al., 
2007) is preferred since the above mentioned complex blend of factors – neurobiological, 
psychological (e.g., depression, catastrophizing, and anxiety), coping styles, and contextual 
factors – contribute to the development and maintenance of chronic pain (Alonso et al., 2004; 
Asmundson & Katz, 2009; Börsbo et al., 2008; Dersh et al., 2001; Ericsson et al., 2002; Means-
Christensen et al., 2008; Ocañez et al., 2010; Sofat et al., 2011; Sullivan et al., 2001). 
1.6 Central versus peripheral causes for chronic pain 
One of the consequences of the discovery of central sensitization is that CNS can change 
pain –e.g., amplification, duration, degree, and spatial extent – so that pain no longer 
directly reflects the peripheral noxious situation (Woolf, 2011). It is unknown whether a 
chronic pain condition can be driven by established central alterations such as central 
hyperexcitability, alterations in pain matrix, and alterations in descending mechanisms 
(facilitation) with very little or no peripheral stimuli or nociception. However, there are 
several indications that central alterations in nociceptive processing are driven by peripheral 
tissue alterations (Gerdle et al., 2008c) and peripheral nociceptive input (Schneider et al., 
2010; Staud, 2010; Staud et al., 2009; Woolf, 2011). 
1.7 The microdialysis technique 
Concerns have been expressed at the lack of success in translating basic science data using 
animals into clinical analgesics (Lascelles & Flecknell, 2010). Microdialysis may be able to 
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replace animal experiments (Langley et al., 2008). The microdialysis technique offers a well-
established in vivo method for studying the local biochemistry of individual tissues in the 
body (Ungerstedt, 1991), e.g., nociceptive and metabolic mechanisms. This technique has 
been used in neuroscience to monitor neurotransmitter release, but has also found 
application in monitoring the biochemistry of peripheral tissues in both animals and 
humans (Ungerstedt, 1991). 
Microdialysis mimics the function of a capillary blood vessel by perfusing a thin dialysis 
tube (catheter) implanted into the tissue with a physiological saline solution. Through 
simple diffusion, substances can move across the dialysis membrane along the concentration 
gradient. The chemical analysis of the dialysate reveals the composition of the extracellular 
fluid. Thus microdialysis allows for continuous sampling of compounds in the interstitial 
space of the muscle, where nociceptor free nerve endings terminate close to the muscle 
fibres, providing accurate information on regional biochemical changes before such 
compounds are diluted and cleared by the circulatory system. The trapezius muscle has 
been used as a human model muscle for chronic myalgia both due to its clinical importance 
and to its accessibility for invasive investigations. Some studies use the masseter, vastus 
lateralis, and gastrocnemius muscles to examine myalgia.  
To determine the concentrations of small molecules such as lactate, pyruvate, glutamate, 
and glucose, a catheter with a 20 kDa cut-off is usually used (Waelgaard et al., 2006). To 
determine the concentrations of larger molecules such as cytokines, a catheter with a 100 
kDa cut-off is usually used (Waelgaard et al., 2006).  
A crucial parameter in microdialysis is relative recovery (RR): the ratio between substance 
concentrations in the dialysate to that in the perfusate (Afinowi et al., 2009; Dahlin et al., 
2010 ; Ungerstedt, 1991). RR is used to determine the true concentration of extracellular 
fluid. Because the perfusate constantly flows across the membrane, a state of equilibrium 
will never be achieved and as a result the dialysate will only represent a certain percentage 
of the actual concentration of the extracellular fluid (Afinowi et al., 2009; Hamrin et al., 
2002). Therefore, the final concentration in the dialysate partially depends on the flow rate of 
the perfusate. Low flow rate results in higher RR; high flow rates, result in lower RR. At a 
very low flow (i.e., < 0.3µl/min), the recovery is near 100%, but factors such as alterations in 
the osmotic pressure, temperature, weight cut-off, area of the membrane, concentration 
gradient, and composition of the perfusate can influence RR (Dahlin et al., 2010 ; Hamrin et 
al., 2002 ; Plock & Kloft, 2005 ). Between cytokines have been reported marked variation in 
RR; molecular weight correlated negatively with RR (Helmy et al., 2009).  
1.8 Aim  
Microdialysis has several important advantages, but studies with patients are expensive and 
time consuming. Hence a systematic review of the literature is needed. Systematic 
knowledge of the results of such studies might help provide new assessment approaches of 
patients with chronic myalgia, new treatments, and new rehabilitation techniques for 
patients with chronic myalgia. Most research on muscle pain has been conducted on 
animals; however, this review will primarily focus on human studies of neck and shoulder 
myalgia, for which the frequently affected trapezius muscle often serves as a model muscle. 
This study systematically reviews studies in the literature that have investigated alterations 
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in metabolic substances, pain-related substances (algesics), and anti-analgesics in different 
chronic muscle pain conditions (mainly myalgia) in humans using microdialysis. This 
systematic review was done to identify potential biomarkers – an objectively measured and 
evaluated indicator of, e.g., normal pathogenic processes (Ptolemy & Rifai, 2010). 
2. Methods 
2.1 Inclusion and exclusion criteria 
Studies that focused on chronic pain conditions affecting human muscles (myalgias) were 
included. To be included, the studies had to use microdialysis and had to use a patient group 
and a healthy control group, so articles concerning only healthy subjects have been excluded. 
2.2 Search strategy  
This review identified the studies fulfilling the above criteria in the systematic review of 
Larsson et al. (Larsson et al., 2007). Furthermore, we modified their search strategy in the 
following ways: ((muscle OR pain) AND microdialysis) OR (muscle AND pain AND 
induced) AND (Humans[Mesh] AND (Clinical Trial[ptyp] OR Meta-Analysis[ptyp] OR 
Review[ptyp]) AND English[lang] AND adult[MeSH] AND "last 10 years"[PDat]).  
Using this strategy, PubMed was searched. From this search, the titles and abstracts were 
scrutinized. If the articles were relevant and necessary, they were read for further 
evaluation. We also checked reference lists of these articles.  If the article was relevant 
according to our aim and inclusion criteria, we listed the results in tables. The tables of the 
different conditions reported the statistics concerning comparisons between the patient 
group and control group with respect to baseline data or corresponding data for all 
investigated substances. Moreover, we listed gender, flow rate, number of subjects in each 
group, and if and how the authors handled RR.  
2.3 Positive outcome with respect to potential biomarker 
A specific substance was classified as a potential biomarker if the majority of studies 
(including the majority of subjects) showed significantly lower or significantly higher 
concentrations in the patient group compared to the controls.  
3. Results 
Using the modified search strategy, we had 441 hits after searching PubMed. After 
screening, we identified 17 articles that fulfilled our inclusion criteria. Thirteen of these were 
not mentioned by Larsson et al. (Larsson et al., 2007). After scrutinizing these 13 articles and 
the articles selected by Larsson et al., we found 22 articles concerning different chronic pain 
conditions involving muscle. These articles are summarized in Tables 1-7. Moreover, we 
identified three articles concerning chronic tendinosis (Table 8). 
3.1 Chronic trapezius myalgia 
For chronic trapezius myalgia, we identified seven groups of patients reported in ten studies 
(Table 1). The majority of the studies reported increases in the interstitial concentrations of 
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lactate (Flodgren et al., 2010; Flodgren et al., 2006; Larsson et al., 2008; Rosendal et al., 2004b; 
Sjogaard et al., 2010). However, the studies conducted by Flodgren et al. (Flodgren et al., 
2010; Flodgren et al., 2006) did not compensate for relative recovery despite the fact that the 
flow rate was relatively high (2µl/min) compared to a flow rate associated with full 
recovery (0.3µ l/min).  
Study Condition 
 Number of 
Subjects, % 
women (W) 
Muscles 
Substances 
investigated
Flow rate 
Results 
(Comparisons between 
patients and HC; p-values) 
Comments 
(Compensated 
for RR (Y/N) 
or low flow 
rate*  
(NA or Y/N) 
Flodgren 
et al.  
(Flodgren 
et al., 2005) 
Chronic shoulder 
pain  
(CSP; n=9),  
100% W 
HC (n=9), 
100%W 
Trapezius 
Glutamate 
PGE2 
 
0.3µl/min 
 
Glutamate-trapezius: ns 
PGE2-trapezius: ns 
 
Compensated 
for RR: N 
Low flow: Y 
Flodgren 
et al.  
(Flodgren 
et al., 2010) 
Chronic trapezius 
myalgia  
(MYA; n=14), 
100% W 
HC  
(compared with 
healthy subjects 
(n=20) in 
(Flodgren et al., 
2006)),  
100% W 
Trapezius 
Lactate 
Pyruvate 
Glutamate 
PGE2 
 
2µl/min 
Lactate-trapezius: ns 
Pyruvate-trapezius: 
Glutamate-trapezius: 
MYA<HC, significant 
PGE2-trapezius: not 
reported. 
Compensated 
for RR: N 
Low flow: N 
Rosendal 
et al. 
(Rosendal 
et al., 
2004b) 
Chronic trapezius 
myalgia  
(MYA; n=19), 
100%W 
HC (n=20), 
100%W 
Trapezius 
Lactate 
Pyruvate 
Glutamate 
5-HT 
 
5µl/min 
Lactate-trapezius:  
MYA > HC; P=0.001 
Pyruvate-trapezius:  
MYA > HC; P=0.001 
Glutamate-trapezius:  
MYA > HC; P=0.05 
5-HT-trapezius: 
MYA > HC; P=0.01 
Compensated 
for RR: Y 
Low flow: NA 
Rosendal 
et al. 
(Rosendal 
et al., 2005) 
Chronic trapezius 
myalgia  
(MYA; n=19), 
100%W 
HC (n=20), 
100%W 
Trapezius 
K+ 
LDH 
IL-6  
Collagen 
turnover 
 
5µl/min 
K+-trapezius:  
MYA > HC;  
P=significant 
LDH-trapezius: ns 
IL-6-trapezius: ns 
Collagen turnover- 
trapezius: ns 
Compensated 
for RR: Y 
Low flow: NA 
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Study Condition 
 Number of 
Subjects, % 
women (W) 
Muscles 
Substances 
investigated
Flow rate 
Results 
(Comparisons between 
patients and HC; p-values) 
Comments 
(Compensated 
for RR (Y/N) 
or low flow 
rate*  
(NA or Y/N) 
Gerdle  
et al.  
(Gerdle et 
al., 2008b) 
Chronic trapezius 
myalgia  
(MYA; n=19), 
100%W 
Chronic whiplash 
associated 
disorders  
(WAD; n=22), 
100%W 
HC (n=20),  
100%W 
 
Trapezius 
BKN 
Kallidin 
5µl/min 
BKN-trapezius:  
No group differences.  
Kallidin-trapezius: 
MYA>HC;  
P=0.018 
No other group differences 
for this substance.  
Compensated 
for RR: Y 
Low flow: NA 
Larsson  
et al. 
(Larsson et 
al., 2008) 
Chronic trapezius 
myalgia  
(MYA; n=20), 
100%W 
HC (n=20), 
100%W 
 
Trapezius 
Lactate 
Pyruvate 
Glutamate 
5-HT 
K+ 
BKN 
GM-CSF 
IL-1ǃ 
IL-6 
IL-8 
TNF-ǂ 
IL-2 
IL-4 
IL-5 
IL-10 
 
5µl/min 
Lactate-trapezius: ns 
Pyruvate-trapezius:  
MYA > HC; P=0.032 
Glutamate-trapezius:  
MYA > HC; P=0.005 
5-HT-trapezius:  
MYA > HC; P=0.023 
K+-trapezius: ns 
BKN- trapezius: ns 
GM-CSF- trapezius: ns 
IL-1ǃ-trapezius: ns 
IL-6-trapezius: ns 
IL-8-trapezius: ns 
TNF-ǂ-trapezius: ns 
IL-2-trapezius: ns 
IL-4-trapezius: ns 
IL-5-trapezius: ns 
IL-10-trapezius: ns 
Compensated 
for RR: Y 
Low flow: NA 
Ghafouri 
et al. 
(Ghafouri 
et al., 2010) 
Chronic  
trapezius 
myalgia,  
(MYA; n=18), 
100%W 
HC (n=30), 
100%W 
 
Trapezius 
5-HT 
 
5µl/min 
5-HT- trapezius: MYA>HC, 
P=0.044 
Compensated 
for RR: Y 
Low flow: NA 
www.intechopen.com
 
Biomarker 
 
110 
Study Condition 
 Number of 
Subjects, % 
women (W) 
Muscles 
Substances 
investigated
Flow rate 
Results 
(Comparisons between 
patients and HC; p-values) 
Comments 
(Compensated 
for RR (Y/N) 
or low flow 
rate*  
(NA or Y/N) 
Ghafouri 
et al. 
(Ghafouri 
et al., 2011) 
Chronic trapezius 
myalgia,  
(MYA; n=11), 
100%W 
HC (n=11), 
100%W 
Trapezius 
PEA 
SEA 
5µl/min 
PEA-trapezius:  
MYA>HC, P=0.011 
SEA-trapezius:  
MYA>HC, P=0.002 
(The statistics are for 
dialysate concentrations, but 
significant differences were 
found  when compensated 
for RR)  
Compensated 
for RR: Y 
Low flow: NA 
Sjøgaard  
et al 
(Sjogaard 
et al., 2010) 
Chronic trapezius 
myalgia (MYA; 
n=43), 100%W 
HC (n=19), 
100%W 
Trapezius 
Lactate 
Pyruvate 
Glucose 
K+ 
5µl/min 
Lactate-trapezius: 
MYA>HC, significant 
Pyruvate-trapezius: 
MYA>HC, significant 
Glucose-trapezius: ns 
K+-trapezius: ns 
 
Compensated 
for RR: Y 
Low flow: NA 
Shah  
et al  
(Shah et 
al., 2005) 
Myofascial 
trapezius pain 
with active 
trigger point 
(MFactive; n=3) 
HC with latent 
trigger point 
(HClatent; n=3) 
HC without 
trigger point 
(HC;n=3) 
Trigger points of 
Trapezius 
BKN 
CGRP 
Substance P 
IL-1ǃ 
TNF-ǂ 
5-HT 
Norepineph
rine 
H+ 
1and 2 
µl/min  
BKN-trapezius: 
MFactive>two other groups; 
P<0.01 
CGRP-trapezius: 
MFactive>two other groups; 
P<0.01 
Substance P- trapezius: 
MFactive>two other groups; 
P<0.01 
IL-1ǃ-trapezius: 
MFactive>two other groups; 
P<0.01 
TNF-ǂ-trapezius: 
MFactive>two other groups; 
P<0.01 
5-HT-trapezius: 
MFactive>two other groups; 
P<0.01 
Norepinephrine-trapezius: 
MFactive>two other groups; 
P<0.01 
H+-trapezius: MFactive>two 
other groups;  
P<0.01 
Compensated 
for RR: Y 
Low flow: NA 
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Study Condition 
 Number of 
Subjects, % 
women (W) 
Muscles 
Substances 
investigated
Flow rate 
Results 
(Comparisons between 
patients and HC; p-values) 
Comments 
(Compensated 
for RR (Y/N) 
or low flow 
rate*  
(NA or Y/N) 
Shah et al. 
(Shah et 
al., 2008) 
Myofascial 
trapezius pain 
with active 
trigger point 
(MFactive; n=3) 
HC with latent 
trigger point 
(HClatent; n=3) 
HC without 
trigger point 
(HC; n=3) 
Trigger points of 
Trapezius 
Gastrocnemius 
medialis without 
trigger points 
BKN 
CGRP 
Substance P 
IL-1ǃ 
TNF-ǂ 
IL-6 
IL-8 
5-HT 
Norepineph
rine 
H+ 
1 and 
2µl/min 
BKN-gastrocnemius: 
MFactive>2 other groups; 
Sign 
CGRP-gastrocnemius: 
MFactive>2 other groups; 
Sign 
Substance P-gastrocnemius: 
MFactive>2 other groups; 
Sign 
IL-1ǃ-gastrocnemius: 
MFactive>2 other groups; 
Sign 
TNF-ǂ-gastrocnemius: 
MFactive>2 other groups; 
Sign 
5-HT-gastrocnemius: 
MFactive>2 other groups; 
Sign 
Norepinephrine-trapezius: 
MFactive>2 other groups; 
Sign 
H+-gastrocnemius: 
MFactive>2 other groups; 
Sign 
Comparisons between trapezius 
(T) and gastrocnemius (G) in 
MFactive:  
BKN: T>G; Sign 
CGRP: T>G; Sign 
Substance P: T>G; Sign 
IL-1ǃ: T>G; Sign 
TNF-ǂ: T>G; Sign 
IL-6: T>G; Sign 
IL-8: T>G; Sign 
5-HT: T>G; Sign 
Norepinephrine: T>G; Sign 
H+:ns 
Comparisons between trapezius 
(T) and gastrocnemius (G) in 
MFlatent:  
BKN, IL-1ǃ, IL-6, IL-8, 5-HT, 
Norepinephrine, H+: ns 
CGRP: T>G; Sign 
Compensated 
for RR: Y 
Low flow: NA 
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Study Condition 
 Number of 
Subjects, % 
women (W) 
Muscles 
Substances 
investigated
Flow rate 
Results 
(Comparisons between 
patients and HC; p-values) 
Comments 
(Compensated 
for RR (Y/N) 
or low flow 
rate*  
(NA or Y/N) 
Substance P: T>G; Sign 
TNF-ǂ: T>G; Sign 
Comparisons between trapezius 
(T) and gastrocnemius (G) in 
HC: 
 BKN: T>G; Sign 
Other substances: ns 
*Low flow rate associated with 100% relative recovery was defined as 0.3µl/min. 
Table 1.  Studies of chronic trapezius myalgia. The results of the different substances are 
baseline data. Healthy controls are abbreviated as HC. The bold horizontal lines indicate 
different patient groups.  
A similar pattern was noted for the majority of studies reporting increased interstitial 
concentrations of pyruvate (Flodgren et al., 2010; Flodgren et al., 2006; Larsson et al., 2008; 
Rosendal et al., 2004b; Sjogaard et al., 2010). Flodgren et al. did not show any significant 
differences for pyruvate (Flodgren et al., 2010; Flodgren et al., 2006).  
Three studies that focused on chronic trapezius myalgia investigated the interstitial 
muscle concentration of glutamate (Flodgren et al., 2005; Larsson et al., 2008; Rosendal et 
al., 2004b). In two of these studies (Larsson et al., 2008; Rosendal et al., 2004b), which were 
markedly larger than the third study (Flodgren et al., 2005), revealed significant increases 
in the interstitial concentrations of glutamate. In all the studies investigating glutamate, 
the interstitial muscle concentration of 5-HT was significantly increased (Ghafouri et al., 
2010; Larsson et al., 2008; Rosendal et al., 2004b; Shah et al., 2008; Shah et al., 2005). 
Furthermore, glutamate was also increased in patients with chronic WAD (Table 2) 
(Gerdle et al., 2008c).  
Four studies examined the interstitial concentrations of BKN and/or Kallidin (Gerdle et al., 
2008b; Larsson et al., 2008; Shah et al., 2008; Shah et al., 2005). Shah et al. (Shah et al., 2008; 
Shah et al., 2005) found increased levels of BKN in subjects with active trigger points and the 
levels were higher in the trapezius (with pain) than in a pain-free distant muscle. In contrast, 
two studies - a field study and a laboratory study - found no differences between patients 
and controls (Gerdle et al., 2008b; Larsson et al., 2008).  Kallidin was only investigated in one 
study and this study reported significantly higher interstitial levels in patients with chronic 
trapezius myalgia (Gerdle et al., 2008b). 
Several studies have investigated cytokines, but only Shah et al. found significant 
differences for active trigger points (Shah et al., 2008; Shah et al., 2005). These authors also 
have compared the levels of cytokines in the myalgic trapezius (trigger points) with a 
muscle without pain and found higher levels in the aching muscle. These studies, however, 
are limited because their sample size was small. Larger studies have not found elevated 
levels of cytokines (Larsson et al., 2008; Rosendal et al., 2005). In three relatively large 
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studies, potassium revealed no consistent pattern (Larsson et al., 2008; Rosendal et al., 2005; 
Sjogaard et al., 2010). PGE2 was not increased in two groups of patients (Flodgren et al., 
2005; Flodgren et al., 2010; Flodgren et al., 2006), but the first of these groups was relatively 
small (Flodgren et al., 2005) and the other had possible methodological drawbacks related to 
RR (Flodgren et al., 2010; Flodgren et al., 2006).  
Study Condition 
 Number of 
Subjects, % 
women (W) 
Muscles 
Substances 
investigated 
Flow rate 
Results 
(Comparisons between 
patients and HC;  
p-values) 
Comments 
(Compensated for 
RR (Y/N) or low 
flow rate*  
(NA or Y/N) 
Gerdle  
et al. 
(Gerdle et 
al., 2008c) 
Chronic 
whiplash 
associated 
disorders 
(WAD; n=22), 
100% W 
HC (n=20), 
100% W 
 
Trapezius 
Lactate
Pyruvate 
Glutamate 
K+ 
5-HT 
IL-6 
 
5µl/min 
Lactate-trapezius: ns
Pyruvate-trapezius: ns 
Glutamate-trapezius: ns
K+- trapezius: ns 
5-HT-trapezius: 
WAD>HC; P=0.05 
IL-6-trapezius: 
WAD>HC; P=0.008 
Compensated for 
RR: Y 
Low flow: NA 
Gerdle 
 et al. 
(Gerdle et 
al., 2008b) 
Chronic 
trapezius 
myalgia  
(MYA; n=19), 
100% W 
Chronic 
whiplash 
associated 
disorders 
(WAD; n=22), 
100% W 
HC (n=20), 
100%W 
 
Trapezius 
BKN
Kallidin 
 
5µl/min 
 
BKN- trapezius: No 
group differences.  
Kallidin-trapezius: 
MYA>HC; P=0.018 
No other group 
differences for this 
substance.  
Compensated for 
RR: Y 
Low flow: NA 
*Low flow rate associated with 100% relative recovery was defined as 0.3µl/min. 
Table 2. Studies of chronic WAD. The results of the different substances are baseline data. 
Healthy controls are abbreviated as HC. 
In two studies, Shah et al. investigated P and CGRP (Shah et al., 2008; Shah et al., 2005). 
They found significant increases in active trigger points in the trapezius and found that 
these levels were higher in the aching trapezius than in a distant pain-free muscle.  
Substances only reported in single studies/patient groups were glucose (no difference) 
(Sjogaard et al., 2010), norepinephrine (significant difference) (Shah et al., 2008; Shah et al., 
2005), and H+ (significant difference) (Shah et al., 2008; Shah et al., 2005). 
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3.2 Chronic WAD 
We identified two studies (Table 2) using the same material concerning patients with 
chronic WAD (Gerdle et al., 2008b; Gerdle et al., 2008c), and 5-HT and IL-6 were 
significantly higher in WAD than in HC. No differences were found in the concentrations of 
investigated metabolites, potassium, glutamate, BKN, or kallidin compared with healthy 
controls.  
3.3 Fibromyalgia 
Two studies investigated fibromyalgia patients (Table 3). In the larger study investigating 
the painful trapezius muscle of fibromyalgia patients, significantly higher interstitial 
concentrations of lactate and pyruvate were found compared to healthy controls (Gerdle et 
al., 2010). In the other study, the vastus lateralis muscle was investigated in eight patients 
with fibromyalgia and the authors reported no differences in concentrations of lactate 
compared to controls (McIver et al., 2006). It is unclear from this study if the vastus lateralis 
was habitually painful and/or painful at palpation (e.g., tender point examination). 
Moreover, no compensation for RR was done despite a relatively high flow rate.  
Study Condition 
 Number of 
Subjects, % 
women (W) 
Muscles 
Substances 
investigated 
Flow rate 
Results 
(Comparisons between 
patients and HC;  
p-values) 
Comments 
(Compensated 
for RR (Y/N) or 
low flow rate* 
(NA or Y/N) 
Gerdle  
et al.  
(Gerdle et 
al., 2010) 
Fibromyalgia 
(FM; n=19),  
100% W 
HC (n=19),  
100% W 
 
Trapezius 
Lactate 
Pyruvate 
Glutamate 
 
0.3µl/min 
 
Lactate-trapezius: 
FM>HC; P=0.039 
Pyruvate-trapezius: 
FM>HC; P=0.001 
Glutamate-trapezius: 
ns. 
 
Compensated for 
RR: N 
Low flow: Y 
McIver  
et al 
(McIver et 
al., 2006) 
Fibromyalgia 
(FM; n=8), 
100%W 
HC (n=8),  
100% W 
Vastus lateralis 
Lactate 
 
2µl/min 
 
Lactate-vastus: ns 
 
Compensated for 
RR: N 
Low flow: N 
*Low flow rate associated with 100% relative recovery was defined as 0.3µl/min  
Table 3. Studies of fibromyalgia. The results of the different substances are baseline data. 
Healthy controls are abbreviated as HC. 
3.4 Temporomandibular pain disorders  
Compared to the healthy controls, fibromyalgia patients had increased 5-HT in the masseter 
muscle (Ernberg et al., 1999). Compared to the healthy controls, myofascial 
temporomandibular disorder patients had significantly higher glutamate levels (Castrillon 
et al., 2010) (Table 4). 
www.intechopen.com
Potential Muscle Biomarkers of Chronic Myalgia in Humans –  
A Systematic Review of Microdialysis Studies 
 
115 
Study Condition 
Number of Subjects, 
% women (W) 
Muscles 
Substances 
investigated 
Flow rate 
Results 
(Comparisons 
between patients 
and HC; p-values)
Comments 
(Compensated 
for RR (Y/N) or 
low flow rate* 
(NA or Y/N) 
Ernberg  
et al  
(Ernberg et 
al., 1999) 
Fibromyalgia  
(FM; n=18),  
100%W 
Localized myalgia of 
the 
temporomandibular 
system  
(LM; n=17), 76% W 
HC (n=10), 60%W 
Masseter 
5-HT 
(corrected for 
S-5-HT) 
 
7µl/min 
5-HT  
(corrected for S-5-
HT)-trauma-
masseter: 
FM>HC:  
P=0.05 
5-HT  
(corrected for S-5-
HT)-baseline-
masseter: no 
group differences 
Compensated for 
RR: N, but 
corrected for S-
5-HT 
Low flow:N 
Hedenberg-
Magnusson  
et al 
(Hedenberg-
Magnusson  
et al., 2001) 
Fibromyalgia  
(FM; n=19),  
89%W 
Localized myalgia of 
the 
temporomandibular 
system  
(LM; n=19), 74%W 
HC (n=11), 64% W 
Masseter 
PGE2 
Leukotriene 
B4(LTB4) 
 
7µl/min 
PGE2-masseter: ns 
LTB4-masseter: 
FM>LM; P=0.05 
Compensated for 
RR: N 
Low flow: N 
Castrillon 
(Castrillon et 
al., 2010)  
Myofascial 
temporomandibular 
disorder pain  
(TMD; n=13), 77%W 
HC (n=10), 80%W 
Masseter 
Glutamate 
 
2µl/min 
 
Glutamate-
masseter: 
TMD> HC; 
P=0.023 
 
Compensated for 
RR:  
Low flow: 
*Low flow rate associated with 100% relative recovery was defined as 0.3µl/min.  
Table 4. Studies of temporomandibular pain disorders. The results of the different 
substances are baseline data. Healthy controls are abbreviated as HC. 
3.5 Chronic tension type headaches  
In two studies of one group of patients (Ashina et al., 2002; Ashina et al., 2003) with chronic 
tension headaches, no differences were found in metabolites and some algesic substances 
(e.g., BKN and PGE2) in the trapezius muscle (Table 5). 
3.6 Polymyalgia rheumatica  
We found two studies of polymyalgia rheumatica based on the same groups of subjects 
(Kreiner & Galbo, 2011; Kreiner et al., 2010) (Table 6). These two studies reported marked 
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alterations in cytokines but also to some extent in algesic substances such as glutamate in 
two muscles. These two studies also reported 5-HT in one muscle and in BKN in one 
muscle. Interestingly, all alterations were normalized after prednisolone treatment.  
Study Condition 
Number of Subjects, 
% women (W) 
Muscles 
Substances 
investigated
Flow rate 
Results 
(Comparisons 
between patients 
and HC;  
p-values) 
Comments 
(Compensated  
for RR (Y/N)  
or low flow  
rate*  
(NA or Y/N) 
Ashina  
et al. 
(Ashina et 
al., 2003) 
Chronic tension-type 
Headache  
(CTTH; n=16),  
63% W 
HC  
(n=17),  
71% W 
Trapezius 
Pyruvate 
Glucose 
Urea 
Glutamate 
K+ 
BKN  
PGE2 
ATP 
2µl/min 
Pyruvate-trapezius: 
ns 
Glucose-trapezius: 
ns 
Urea-trapezius: ns 
Glutamate-
trapezius: ns  
K+-trapezius: ns 
BKN-trapezius: ns 
PGE2-trapezius: ns 
ATP-trapezius: ns 
Compensated for 
RR: Y 
Low flow: NA 
Ashina  
et al. 
(Ashina et 
al., 2002) 
Chronic tension-type 
Headache  
(CTTH;  
n=16),  
63% W 
HC (n=17),  
71% W 
Trapezius 
Lactate 
 
2µl/min 
Lactate- trapezius: 
ns 
Compensated for 
RR: Y 
Low flow: NA 
*Low flow rate associated with 100% relative recovery was defined as 0.3µl/min.  
Table 5. Studies of chronic tension type headaches. The results of the different substances 
are baseline data. Healthy controls are abbreviated as HC. 
3.7 Mitochondrial myopathy 
In a study of mitochondrial myopathy that included four patients, no significant differences 
were found for metabolites, glutamate, hypoxanthine, urate, and aspartate (Table 7).  
3.8 Chronic tendinosis  
We also found three studies that focused on chronic tendinosis (Table 8). These three 
studies are small and have investigated different tendons with pain. The interstitial 
concentrations of glutamate, PGE2, and lactate were investigated, but no consistent pattern 
with respect to these substances was found.  
www.intechopen.com
Potential Muscle Biomarkers of Chronic Myalgia in Humans –  
A Systematic Review of Microdialysis Studies 
 
117 
Study Condition
 Number of 
Subjects, % 
women(W) 
Muscles 
Substances 
investigated 
Flow rate 
Results
(comparisons between patients 
and HC; p-values) 
Comments 
(Compensated 
for RR (Y/N) or 
low flow rate* 
(NA or Y/N) 
Kreiner & 
Galbo 
(Kreiner & 
Galbo, 
2011) 
Polymyalgia 
rheumatica 
(PMR)(n=20), 
60%W 
Healthy 
controls (HC) 
(n=20), 65%W 
Trapezius 
Vastus 
lateralis 
Lactate
Pyruvate 
Glutamate 
5-HT 
BKN 
PGE2 
K+ 
ATP 
3µl/min 
 
Lactate –trapezius: PMR >HC; 
P=0.05 
Pyruvate –trapezius: ns 
Glutamate–trapezius: PMR 
>HC; P=0.05 
5-HT–trapezius: ns 
BKN–trapezius: ns 
PGE2–trapezius: ns 
K+–trapezius: ns 
ATP–trapezius: ns 
Lactate–vastus: ns 
Pyruvate–vastus: ns 
Glutamate–vastus: PMR >HC; 
P=0.05 
5-HT–vastus: PMR >HC; P=0.05 
BKN–vastus: ns  
PGE2–vastus: PMR >HC; P=0.05
K+–vastus: ns 
ATP–vastus: ns 
Compensated 
for RR: Y 
Low flow: NA 
Kreiner et 
al.  
(Kreiner et 
al., 2010) 
Polymyalgia 
rheumatica 
(PMR)(n=20), 
60%W 
Healthy 
controls (HC) 
(n=20), 65% W 
Trapezius 
Vastus 
lateralis 
IL-1ǂ/ǃ
IL-1 receptor 
antagonist 
(IL-1Ra) 
IL-6 
IL-8 
TNF-ǂ 
Monocyte 
chemoattract
ant 
protein 
1(MCP-1) 
3µl/min 
 
IL-1ǂ–trapezius: PMR >HC; 
P=0.001 
IL-1ǃ–trapezius: PMR >HC; 
P=0.01 
IL-1Ra–trapezius: PMR >HC; 
P=0.01 
IL-6–trapezius: PMR >HC; 
P=0.01 
IL-8–trapezius: PMR >HC; 
P=0.05 
TNF-ǂ–trapezius: PMR >HC; 
P=0.05 
MCP-1–trapezius: PMR >HC; 
P=0.05 
IL-1ǂ–vastus: PMR >HC; P=0.01 
IL-1ǃ–vastus: PMR >HC; P=0.05 
IL-1Ra–vastus: PMR >HC; 
P=0.05 
IL-6–vastus: PMR >HC; P=0.05 
IL-8–vastus: PMR >HC; P=0.05 
TNF-ǂ–vastus: PMR >HC; P=ns 
MCP-1–vastus: PMR >HC; 
P=0.05
Compensated 
for RR: Y 
Low flow: NA 
*Low flow rate associated with 100% relative recovery was defined as 0.3µl/min. 
Table 6. Studies of Polymyalgia rheumatica. The results of the different substances are 
baseline data. Healthy controls are abbreviated as HC.  
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Study Condition 
 Number of 
Subjects, % 
women(W) 
Muscles 
Substances 
investigated 
Flow rate 
Results 
(Comparisons 
between patients and 
HC; p-values) 
Comments 
(Compensated 
for RR (Y/N) or 
low flow rate* 
(NA or Y/N) 
Axelson  
et al 
(Axelson et 
al., 2002) 
Mitochondrial 
Myopathy (MM; 
n=4); 50% W 
HC (n=11), 36% 
W 
Tibialis anterior 
Lactate 
Pyruvate 
Glutamate 
Hypoxanthine 
Urate 
Aspartate 
0.3µl/min 
Lactate-tibialis: ns 
Pyruvate-tibialis: ns 
Glutamate-tibialis: ns 
Hypoxanthine-
tibialis: ns 
Urate-tibialis: ns 
Aspartate-tibialis: ns 
Compensated for 
RR: N 
Low flow: Y 
*Low flow rate associated with 100% relative recovery was defined as 0.3µl/min. 
Table 7. Studies of mitochondrial myopathy. The results of the different substances are 
baseline data. Healthy controls are abbreviated as HC. 
Study Condition 
 Number of 
Subjects, % 
women(W) 
Tendon 
Substances 
investigated 
 
Results 
(Comparisons between 
patients and HC;  
p-values) 
Comments 
(Compensated for 
RR (Y/N) or low 
flow*  
(NA or Y/N)) 
Alfredson 
et al 
(Alfredson et 
al., 2000) 
Tennis Elbow 
(TE; n=4),  
25% W 
HC (n=4), 
50%W 
Extensor carpi 
radialis brevis 
tendon 
Glutamate 
PGE2 
 
Glutamate: ns 
PGE2:TE>HC;P< 0.001 
 
Compensated 
for RR: N 
Low flow: Y 
Alfredson 
et al 
(Alfredson et 
al., 2001) 
Jumpers’ knee 
(JK; n=5), 
20%W 
HC (n=5), 
20%W 
Patellar tendon 
Glutamate 
PGE2 
 
Glutamate: JK>HC; 
P=0.01 
PGE2: ns 
 
Compensated 
for RR: N 
Low flow: Y 
Alfredson  
et al 
(Alfredson, 
2005) 
Chronic 
Achilles 
tendinosis 
(CAT; n=4), 
0%W 
HC (n=5), 0%W
Achilles tendon
Lactate Lactate: CAT>HC; 
P=0.05 
Compensated 
for RR: N 
Low flow: Y 
*Low flow was defined as 0.3µl/min. 
Table 8. Studies of tendons with chronic pain. The results of the different substances are 
baseline data. Healthy controls are abbreviated as HC.  
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4. Discussion  
4.1 Metabolites 
The majority of studies concerning the trapezius in chronic trapezius myalgia have reported 
increases in the interstitial concentrations of lactate and pyruvate (Flodgren et al., 2010; 
Flodgren et al., 2006; Larsson et al., 2008; Rosendal et al., 2004b; Sjogaard et al., 2010). 
However, Flodgren et al. (Flodgren et al., 2010; Flodgren et al., 2006) did not compensate for 
RR and their results might be biased.  
There are several possible explanations for the generally higher interstitial levels of pyruvate 
levels in chronic trapezius myalgia and in the trapezius of patients with FMS. For example, 
changes in the lactate-pyruvate metabolism via lactate dehydrogenase isoforms may result 
in higher pyruvate levels (Philip et al., 2005). Another explanation is a reduction in tissue 
oxygenation in FMS (Bengtsson, 2002) and chronic trapezius myalgia (Larsson et al., 2004), 
reductions that may result in higher pyruvate and higher lactate concentrations due to a 
shift towards an anaerobic state. A lower fitness level is a third explanation as a low fitness 
level means more frequent reliance on anaerobic metabolism. However, it is unknown if a 
general deconditioning in these two pain conditions involves the postural trapezius. The 
aerobic capacity of a muscle is largely governed by the number of mitochondria and their 
enzymes (Weibel & Hoppeler, 2005). The mitochondrial density increases as result of 
exercise and this increased density affects the level of metabolites (i.e., enhanced aerobic 
capacity) (Norrbom, 2008). Lower capillary density and/or enzymes associated with aerobic 
metabolism have been reported in FMS and in chronic trapezius myalgia (Larsson et al., 
2004; Lindh et al., 1995). For FMS and chronic trapezius myalgia, the trapezius muscle fibres 
can appear with alterations in mitochondrial content and distribution, e.g., moth-eaten 
fibres and ragged red-fibres (Bengtsson, 2002; Bengtsson et al., 1986; Larsson et al., 2000; 
Larsson et al., 2004).  
The role of lactate is complex. Lactate may assist in the detection of exercise stress before 
tissue damage occurs and can be exchanged rapidly among tissue compartments where it 
may be oxidized as a fuel or reconverted to form pyruvate or glucose (Gladden, 2004; Kim et 
al., 2007; Philip et al., 2005; Robergs et al., 2004). Lactate is also involved in peripheral 
nociception and it appears to facilitate the response of the acid-sensing ion channel 3 (ASIC-
3) to low pH (Kim et al., 2007). Such ASIC channels are considered to be molecular 
transducers for nociception and mechanosensation (Kim et al., 2007). 
To summarize, most studies of myalgic trapezius muscles show significant increases in 
interstitial levels of lactate and pyruvate. These results might be explained by decreased 
fitness level, reduced tissue oxygenation, increased muscle activation, and/or damaged 
mitochondria. 
4.2 Pain-related substances 
4.2.1 Glutamate 
Two of the studies of chronic trapezius myalgia (Larsson et al., 2008; Rosendal et al., 2004b), 
which are markedly larger than the third study (Flodgren et al., 2005), found significant 
increases in the interstitial concentrations of glutamate. A possible difference between 
subjects of these studies may contribute to the inconsistent glutamate finding. The myalgic 
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subjects studied by Larsson et al. and Rosendal et al. (Larsson et al., 2008; Rosendal et al., 
2004b) comprised subjects reporting considerable pain and had distinct current muscular 
signs confirmed at clinical examination. The pain history, the present pain, and clinical 
muscular neck status of the subjects are very sparsely presented in the Flodgren study 
(Flodgren et al., 2005). Moreover, one study found the painful masseter was significantly 
associated with increased glutamate (Castrillon et al., 2010).  
Glutamate, a pain modulator in the human central nervous system, acts via the N-methyl-D-
aspartate (NMDA) receptor (Coggeshall & Carlton, 1997) (Hudspith, 1997) and influences 
peripheral pain processing (Carlton, 2001; Varney & Gereau, 2002 ), e.g., muscle 
inflammation and delayed onset muscle soreness (Cairns et al., 2001a; Cairns et al., 2001b; 
Cairns et al., 2003; Svensson et al., 2003; Svensson et al., 2005; Tegeder et al., 2002 ). 
Glutamate is released from peripheral afferent nerve terminals (Miller et al., 2011). Studies 
of animals have shown that glutamate receptors are located on the peripheral ends of small-
diameter primary afferents in several tissues such as muscle (Coggeshall & Carlton, 1998). 
Inflammatory animal models reveal increased levels of glutamate in peripheral tissues and 
nociceptive behaviours (Miller et al., 2011). Several studies have demonstrated that 
injections of glutamate increase pain intensity (Cairns et al., 2003; Gazerani et al., 2006). A 
review from 2008 concluded that elevation of interstitial glutamate in skeletal muscle alters 
pain sensitivity in healthy humans and is associated with pain symptoms in some chronic 
non-inflammatory muscle pain conditions (Cairns & Dong, 2008), which are probably 
mediated through activation of peripheral excitatory amino acid receptors located on the 
terminal ends of nociceptors. The present review mainly supports the conclusions of that 
review. However, the interstitial concentrations of glutamate were not increased in the 
trapezius of patients with chronic WAD (Gerdle et al., 2008c) or in patients with 
fibromyalgia (Gerdle et al., 2010). One difference between chronic trapezius myalgia and the 
two other conditions might be the more widespread (spatial) hyperalgesia in the two latter 
conditions (Arendt-Nielsen & Graven-Nielsen, 2003; Wallin et al., 2011). 
4.2.2 Serotonin 
Serotonin (5-hydroxtryptamine, 5-HT) is involved in the central and peripheral modulation 
of nociceptive pain and hyperalgesia (Sommer, 2004). 5-HT is synthesized in brain neurons 
from the essential amino acid tryptophan and released from platelets and mast cells in the 
periphery due to tissue damage (Mense, 1993). Whether 5-HT has an analgesic or 
hyperalgesic action depends on the cell type and type of receptor it targets. Currently, seven 
receptor families have been identified.  These receptors are cell-surface proteins that bind 5-
HT and trigger intracellular changes that influence the behaviour of cells and explain the 
broad physiological actions and distribution of this biochemical mediator. According to 
animal studies, the 5-HT receptor classes currently identified, the 5-HT1 and the 5-HT2, may 
be involved in mainly chemical and thermal hyperalgesia (Ernberg, 2008). 5-HT activates the 
descending endogenous pain system and this inhibits centrally mediated pain transduction 
(Sommer, 2006; Suzuki et al., 2004). In the periphery, 5-HT sensitizes afferent nerve fibres, 
contributing to hyperalgesia in inflammation and nerve injury (Giordano & Rogers, 1989; 
Sommer, 2004; Taiwo & Levine, 1992). Intramuscular administration of 5-HT into the human 
masseter muscle has been demonstrated to induce pain (Ernberg et al., 2006). The studies 
identified in this systematic review concerning chronic trapezius myalgia (Table 1) clearly 
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indicate significantly increased levels of 5-HT in the whole spectrum of severity of chronic 
trapezius myalgia and these findings agree with other studies of muscle pain conditions 
such as myalgic masseter muscle (Ernberg et al., 1999) (Table 4) and chronic whiplash 
associated pain including trapezius pain (Gerdle et al., 2008c) (Table 2). The finding that 
there are higher interstitial levels of 5-HT in chronic trapezius myalgia than in controls at 
rest agrees with other studies that also found that 5-HT is a peripheral pro-nociceptive 
substance activated by afferents and by the release of other substances (Saria et al., 1990; 
Sommer, 2004). The results of the present systematic review clearly indicate that 5-HT can 
be a potential biomarker of different types and severity of chronic myalgia.  
4.2.3 Bradykinin (BKN) and Kallidin (KAL) 
BKN and KAL are kinins – a group of structurally related 9-11 amino acid peptides that are 
produced by kallikrein-mediated enzymatic cleavage of kininogen (Coutaux et al., 2005; 
Riedel & Neeck, 2001; Wang et al., 2006). Kinins mediate their effects via two different G 
protein coupled receptors, B1 and B2, that provoke an increase in intracellular Ca2+ (Meyer et 
al., 2006; Zubakova et al., 2008). In normal tissue in the acute situation, BKN and KAL act 
via the B2 receptor. In the chronic phase of the response of tissue injury and infection, B1 
receptors are expressed by BKN and KAL via this receptor (Calixto et al., 2004; Coutaux et 
al., 2005; Couture et al., 2001; Graven-Nielsen & Mense, 2001; McMahon et al., 2006). 
Interstitial muscle BKN and KAL have been suggested as algesic kinins involved in muscle 
pain. BKN was the first inflammatory mediator recognized to have potent hyperalgesic 
properties (Levine & Reichling, 1999). BKN induces pain and modifies the receptive fields of 
dorsal horn neurons to noxious stimuli in humans when administered in different ways 
(Boix et al., 2005; Meyer et al., 2006). BKN and cytokines are central factors in the link 
between tissue damage and inflammatory responses (Coutaux et al., 2005). Moreover, BKN 
is a potent vasodilatator and is increased in the interstitium of muscle during exercise 
(Clifford & Hellsten, 2004; Schmelz et al., 2003; Stewart & Rittweger, 2006). Animal studies 
have shown that BKN can both excite (i.e., algogenic) and sensitize nociceptors (Levine & 
Reichling, 1999; Wang et al., 2006). The present review identified four studies investigating 
the interstitial concentrations of BKN and/or Kallidin (Gerdle et al., 2008b; Larsson et al., 
2008; Shah et al., 2008; Shah et al., 2005). The relatively small studies conducted by Shah et 
al. (Shah et al., 2008; Shah et al., 2005) clearly indicated that BKN was involved since 
increased levels of BKN in subjects with active trigger points and the levels were higher in 
the trapezius (with pain) than in a pain-free distant muscle. In contrast no significant 
differences in BKN were found between patients and controls in a field study and a 
laboratory study, (Gerdle et al., 2008b; Larsson et al., 2008) The difference in results between 
the above mentioned studies could be due to the fact that alterations in BKN might be very 
localized (i.e., in the trigger points) and not generally found in the aching trapezius muscle. 
KAL was only investigated in one study and increased in chronic trapezius myalgia but not 
in the trapezius of chronic WAD compared to controls (Gerdle et al., 2008b). Clearly, more 
pathophysiological in vivo studies are necessary in order to understand the roles of BKN and 
KAL for nociception and pain in patients with chronic pain.  
4.2.4 Potassium 
Increased interstitial potassium levels may be related to muscle pain (Graven-Nielsen et al., 
1997). Green et al., however, did not find potassium related to acute ischaemic myalgia in 
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healthy subjects (Green et al., 2000). Repetitive work in healthy subjects may increase 
potassium levels (Rosendal et al., 2004a), although in the present systematic review no 
consistent pattern of increased potassium was found in patients with chronic trapezius 
myalgia (Larsson et al., 2008; Rosendal et al., 2005; Sjogaard et al., 2010) (Table 1) or with 
chronic WAD (Table 2).  
4.2.5 Cytokines 
There are several direct and indirect pathways that link cytokines with nociception or 
hyperalgesia (Coutaux et al., 2005; Sommer & Kress, 2004; Uceyler et al., 2009). Four studies 
investigated cytokines in chronic trapezius myalgia, but significant differences were only 
found for active trigger points (Shah et al., 2008; Shah et al., 2005). These studies, however, 
used very few subjects, an obvious limitation.  Larger studies have not found elevated levels 
of cytokines (Larsson et al., 2008; Rosendal et al., 2005). On the other hand, these studies 
might have had some technical problems due to the catheters used, also a limitation. 
However, the chronic WAD study found increased IL-6 (Gerdle et al., 2008c).   
4.3 Anti-analgesic substances 
As is obvious from the above, most studies concern metabolites and algesic substances. 
Little is known about changes in the pain-inhibitory signalling molecules. One interesting 
group of such molecules is the N-acylethanolamines (NAEs), which is a family of 
endogenous lipid mediators that have several roles including the regulation of inflammation 
and pain (Pacher et al., 2006). Examples of NAEs are N-palmitoylethanolamine (PEA), N-
stearoylethanolamine (SEA), N-oleoylethanolamine (OEA), and N-arachidonoylethanolamine 
(anandamide, AEA). The most thoroughly studied of the NAEs is AEA, which interacts with 
cannabinoid receptors. At higher concentrations, AEA also targets transient receptor 
potential (vanilloid-1) receptors and has been shown to have anti-nociceptive actions in a 
number of animal models of pain (Calignano et al., 1998). The present review also includes 
one study of SEA and PEA (Ghafouri et al., 2011), which reported significantly increased 
levels of two NAEs.  
4.4 Other pain conditions identified 
According to our review, microdialysis of painful muscles have also been investigated, but 
these studies have only been based on one group of patients of each condition: polymyalgia 
rheumatic, chronic tension-type headache, and mitochondrial myopathy. Hence no definite 
conclusions concerning potential biomarkers can be drawn for these conditions. The results 
concerning polymyalgia rheumatic were prominent for several algesics including cytokines. 
Kreiner et al. investigated the presence of muscle alterations (Kreiner & Galbo, 2011; Kreiner 
et al., 2010), and they found that the biochemical alterations were normalized after treatment 
with prednisolone. Although more studies are needed, their results suggest that 
intramuscular mechanisms are important.  
In the studies of different chronic tendinosis, the number of patients was low and no 
consistent patterns were seen. Larger studies are needed to identify biochemical 
alterations.  
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4.5 Suggestions with respect to future studies 
The fact that most studies of chronic trapezius myalgia, chronic WAD, and 
temporomandibular pain disorders included women is expected, as the prevalence of these 
conditions are higher in women. Future studies should also include groups of men with 
chronic muscle pain conditions. In addition, it is important to describe the patient group in 
detail with respect to clinically relevant examination parameters. Furthermore, systematic 
descriptions of the patient groups are needed that reflect pain intensity and psychological 
distress as well as consequences such as work participation and sick leave.  A systematic 
description will allow a more accurate characterization of pain severity in a broad context. 
Most studies rely on bivariate correlations between pain descriptors such as pain intensity 
or pressure pain thresholds and the concentration of a certain substance. Multivariate 
correlation analyses and regression analyses are methods that can be used to investigate 
how groups of clinical examination variables, several simultaneous symptoms, and the 
concentrations of several biochemical substances intercorrelate. To better understand the 
potentially complex biochemical situation of the muscle in chronic pain conditions, it is 
necessary to also investigate the multivariate interrelationships between the concentrations 
of the investigated substances. According to ICD, the clinically used pain diagnoses are 
symptom diagnoses based on temporal and anatomical characteristics (e.g., chronic 
lumbago). Hence a certain diagnosis may include patients with different activated 
pathophysiological mechanisms. To identify subgroups of patients with identical 
pathophysiological mechanisms, it is important to use large patient groups and appropriate 
statistical methods (e.g., cluster analysis and principal component analysis).  
5. Conclusion 
This systematic review found that most of the studies focused on trapezius myalgia (seven 
patient groups reported in ten studies), temporomanidibular pain syndromes (two patient 
groups reported in three studies), and fibromyalgia (two patient groups but different 
muscles). Relatively strong scientific support identifies 5-HT as a potential biomarker in 
chronic myalgia. Moderately strong scientific support identifies glutamate, pyruvate, and 
lactate as potential biomarkers in chronic trapezius myalgia. There is a need for larger 
studies of well-characterized patient groups with respect to perceived situations, symptoms, 
and signs so as to investigate several substances simultaneously in order to improve the 
understanding of peripheral nociceptive processes in myalgia.  
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